Tianmu Pharmaceutical: Wholly-owned subsidiary receives Drug Registration Certificate Approval Notification.

Tianmu Pharmaceutical Industry Notice: Recently, the company's wholly-owned subsidiary, Huangshan Tianmu Pharmaceutical Co., Ltd., received the "Drug Re-registration Approval Notification" issued by the Anhui Provincial Drug Administration. This re-registration involves multiple drugs such as Liuwei Dihuang Pill, Yuanhu Zhitong Capsule, and Qiju Dihuang Pill, with approval valid until November 2030. The acquisition of this approval notification provides a guarantee for the stable and continuous qualification of the company's drug production and sales, and is of positive significance for the subsequent production, sales, and promotion. The company will strictly follow the requirements to ensure product quality and continue to provide high-quality products to the market.